Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Bristol, AstraZeneca Rebuffed by FDA Panel on Diabetes Drug
Bristol, AstraZeneca Rebuffed by FDA Panel on Diabetes Drug
Bristol, AstraZeneca Rebuffed by FDA Panel on Diabetes Drug
Submitted by
admin
on July 19, 2011 - 6:11pm
Source:
Bloomberg
News Tags:
FDA
AstraZeneca
diabetes
Bristol-Myers Squibb
Dapagliflozin
Headline:
Bristol, AstraZeneca Rebuffed by FDA Panel on Diabetes Drug
Do Not Allow Advertisers to Use My Personal information
